Name (Synonyms) | Correlation |
---|
There is one clinical trial.
The study is configured as a retrospective and prospective observational study. The study will be multi-center and will involve all COVID-19 pneumonia patients treated with canakinumab administered subcutaneously.
Description: percentage of patients treated with canakinumab sc who do not require intensive care treatment during hospitalization for COVID-19
Measure: intensive care treatment Time: 9 monthsDescription: ICU stay times
Measure: ICU stay times Time: 9 monthsDescription: percentage of patients who died 1 month after treatment
Measure: % died after 1 month after treatment Time: 9 monthsDescription: time of hospitalization
Measure: hospitalization Time: 9 monthsDescription: number of adverse event
Measure: adverse event Time: 9 months